基因重组链激酶治疗急性心肌梗死20例疗效观察  

Therapeutic effect of r-SK on acute myocardial infarction: a report of 20 cases

作　　者：边长勇[1] 秦永文[1] 郑兴[1] 

机构地区：[1]第二军医大学长海医院心血管内科,上海200433

出　　处：《第二军医大学学报》1999年第12期992-993,共2页Academic Journal of Second Military Medical University

摘　　要：目的:观察基因重组链激酶(r-SK)静脉溶栓治疗急性心肌梗死(AMI)的疗效及安全性。方法:应用r-SK静脉溶栓治疗20例AMI患者,观察其血管再通率、不良反应发生率及住院病死率。结果:r-SK静脉溶栓血管再通率为75%;轻度出血发生率为5%,低血压(可在短期内纠正)发生率为15%,发热发生率为15%;5周内住院病死率为10%。结论:r-SK静脉溶栓治疗AMI疗效明确,安全性高。Objective: To observe the therapeutic effect of intravenous thrombolysis of recombinant streptokinase (r SK) on acute myocardial infarction (AMI) and its safety. Methods: Twenty patients with AMI received r SK for thrombolysis.The reopening rate of infarct related artery,side effect and the fatality rate in hospital were observed. Results: The reopening rate of infarct related artery was 75%. The incidence of slight hemorrhage, fever, low blood pressure,which could be corrected in short time, was 5%, 15%, 15%, respectively. The fatality rate 5 weeks after AMI was 10%. Conclusion: The therapeutic effect of r SK in the thrombolytic therapy of AMI is definite and the safety is fine.

关 键 词：心肌梗塞 链激酶 基因重组 r-SK 溶栓疗法 

分 类 号：R542.220.5[医药卫生—心血管疾病]